
- Applied Clinical Trials-11-01-2013
- Volume 22
- Issue 11
Cost Per Visit Trends Higher for Less Established Regions
IMS Health
Many factors affect a sponsor's decision to pick a region in which to conduct a clinical trial. Clinical grant expenditures represent a significant portion of later phase clinical trial budgets. Therefore, the relative cost per visit can play a large role in which region to select.
Figure 1. Cost per visit rate trends, 2008-2010 and 2011-2013.
IMS Health's current analysis demonstrates that the cost per patient visit in the newer, emerging geographies, is growing more rapidly than in more established regions. The established regions (Western Europe, US/Canada, and Australia/New Zealand) have been averaging 8% annual increases from 2011-2013, while grant costs in developing regions (East Asia, Latin America, and Eastern Europe) are growing at two to three times those rates with an average of 23%. Even if these emerging regions are starting off on a lower base as compared to well established regions, the rapid rise in cost in these regions warrant careful consideration in the coming years.
—IMS Health (for more information contact
Articles in this issue
almost 12 years ago
Sponsors Struggle with Data Disclosure Requirementsalmost 12 years ago
Evaluation of Data for Multi-Regional Trials: A Three-Layer Approachalmost 12 years ago
Modeling Successful Phase III Trialsalmost 12 years ago
GCP's Future: Looking Ahead to the Next 20 Yearsalmost 12 years ago
Crunch-Time for Europe's Clinical Trials Rulesalmost 12 years ago
Device Independence is the Future of Clinical Trialsalmost 12 years ago
Business and People November 2013almost 12 years ago
Adoption of Adaptive Trial Designs Poised to Acceleratealmost 12 years ago
Applied Clinical Trials Digital Edition - November 2013Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.